EXECUTIVE EMPLOYMENT AGREEMENT forExecutive Employment Agreement • November 4th, 2019 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”), made between Revance Therapeutics, Inc. (the “Company”) and Mark Foley (“Executive”) (collectively, the “Parties”), is effective as of October 13, 2019 (the “Start Date”).
October 10, 2019 Via EmailRevance Therapeutics, Inc. • November 4th, 2019 • Pharmaceutical preparations • California
AMENDMENT #1 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 4th, 2019 • Revance Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS AMENDMENT #1 TO THE COLLABORATION AND LICENSE AGREEMENT (this “Amendment #1”) is made and entered into effective as of August 22, 2019 (the “Amendment #1 Effective Date”), by and among Revance Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having principal offices at 7555 Gateway Blvd., Newark, CA 94560 (together with its successors and assigns, “Revance”), and Mylan Ireland Ltd., a company organized and existing under the laws of Ireland, having principal offices at South Bank House, Barrow Street, 6th Floor, Dublin, Ireland (together with its successors and assigns, “Mylan”).
